Developer docs
API playgroundTry for free, no card

Search company profiles

IVI RMA GLOBAL

Full company profile

uuid0006nm8

Namestring
IVI RMA GLOBAL
Legal namestring
EQUIPO IVI, S. L.
Company typeenum
Private
Founded yearint
1990
Descriptiontext

IVI RMA Global is a privately held reproductive medicine group operating the world's largest dedicated fertility treatment network. Formed in 2017 through the merger of Spain's IVI (founded 1990 by Profs. José Remohí and Antonio Pellicer) and the US-based RMA (founded 1999 by Drs. Paul Bergh, Richard Scott and Michael Drews), the company runs more than 200 clinical offices and 95+ laboratories across 15 countries in Europe, North America, Latin America, and (as of late 2025) the Middle East, performing 200,000+ assisted reproduction treatments annually and producing 100+ births per day.

The group's clinical platform spans core ART services (in vitro fertilization, intracytoplasmic sperm injection, artificial insemination, egg and sperm donation, fertility preservation including oocyte vitrification), advanced laboratory techniques (time-lapse embryo monitoring, MACS sperm selection, extended blastocyst culture), and a full genetic testing suite (PGT-A, PGT-SR, PGT-M, NIPT, carrier and sperm aneuploidy testing). It is supported by 7 research centers and 350+ researchers who have published 3,000+ scientific papers, alongside a global education division and the regional brands Boston IVF, Conceptions, Create Fertility, Genera, Demetra, Livio, Vitanova, Carl Von Linne, TRIO, Ferticare, Ginemed, Ginefiv, and Art Fertility.

IVI RMA generates revenue primarily from per-cycle clinical treatment fees across its global clinic network, supplemented by a recently launched US subscription membership product (with Costco and Sesame) priced at $99-$119 per month. The company is KKR-backed and has executed roughly $985M of M&A in 2025 alone, including the $535M Eugin North America acquisition and the ~$450M ART Fertility Clinics deal that established the Middle East as its fifth geographic region. Customers are overwhelmingly individual patients seeking fertility care, supplemented by enterprise partnerships with retailers, telehealth platforms, and advocacy organizations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersValencia, Spain
HQ citystring
Valencia
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
assisted reproductive technology, in vitro fertilization, fertility treatment services, reproductive medicine clinics, fertility preservation services
Industry4 codes
1Fertility, Reproductive Endocrinology & IVF Centers
CodeHLAFAJADPrimaryYes
2Reproductive Endocrinology & Infertility (IVF/Fertility)
CodeHLAKAJACPrimaryNo
3Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation)
CodeHLALAHAAPrimaryNo
4Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
CodeHLAAALAJPrimaryNo
NAICS code3 codes
  • Family Planning Centers621410
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Specialty Outpatient Facilities, Nec8093
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Reproductive Medicine / Fertility Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Fertility Treatment Services
TypeSubscription Recurring
Description

IVI RMA Global generates revenue through providing assisted reproductive services including IVF, artificial insemination, egg donation, fertility preservation, and related treatments. Services are offered through a network of 200+ clinical offices across 15 countries.

ivirma.com
2Membership-based Fertility Care
TypeSubscription Recurring
Description

Partnership with Costco and Sesame offers fertility care through a monthly membership model starting at $119 per month ($99 for Costco members), providing end-to-end fertility care including virtual access to reproductive specialists.

benefitnews.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Costco Membership Fertility Care Plan
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly membership starting at $119 per month ($99 for Costco members) for affordable end-to-end fertility care. IVF medications alone can cost over $7,000 per cycle without insurance.

benefitnews.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

IVI RMA Global operates a global network of fertility clinics providing assisted reproductive technology (ART) services including in vitro fertilization (IVF), artificial insemination, egg donation, fertility preservation, and preimplantation genetic testing. The group delivers these services through 200+ clinical offices and 95+ labs across 15 countries, supported by advanced laboratory techniques such as time-lapse embryo monitoring, ICSI, oocyte vitrification, MACS sperm selection, and extended embryo culture to blastocyst stage.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 100+ babies born daily thanks to IVI RMA Global
+2 more records
Product overview1 text field

IVI RMA Global is a comprehensive fertility care platform operating as the world's leading reproductive medicine group with a multi-brand, multi-region portfolio. The company offers a unified platform of assisted reproductive technology (ART) services comprising core clinical treatments (Artificial Insemination, In Vitro Fertilization, Egg Donation, Fertility Preservation), advanced laboratory techniques (Oocyte Vitrification, Time-Lapse Monitoring, ICSI, MACS, Extended Embryo Culture), and genetic testing services (PGT-A, PGT-SR, PGT-M, NIPT, Carrier Genetic Testing). The platform is organized across regional brands including IVI, RMA Network, Boston IVF, Conceptions, Ginemed, Ginefiv, Art Fertility, Create Fertility, Genera, Demetra, Livio, Vitanova, Carl Von Linne, TRIO Fertility, and Ferticare, spanning 15 countries with over 200 clinical offices and 95+ laboratories. The group also provides complementary services including global education programs (postgraduate studies, online courses, training & consulting) and research services through its Global Research Alliance (7 research centers, 15 research areas).

Product and service15 records
1In Vitro Fertilization (IVF)
CategoryCore Treatment Service
Description

A procedure uniting the ovum with the spermatozoon in the laboratory (in vitro) to obtain fertilized embryos for transfer to the mother's uterus, using either conventional IVF or ICSI. Offered to women and couples needing medical assistance to conceive.

2Artificial Insemination
CategoryCore Treatment Service
Description

A procedure in which a prepared semen sample is deposited inside the woman's uterus to increase the potential of the spermatozoa and improve the chance of fertilization. Offered to couples and individuals seeking less invasive fertility treatment.

3Egg Donation
4Fertility Preservation
5Sperm Donation
6Preimplantation Genetic Testing for Aneuploidies (PGT-A)
CategoryGenetic Testing Service
Description

A test that detects numerical alterations in an embryo's chromosomes, identifying whether there are more or fewer chromosomes than the normal 46. Offered to patients undergoing IVF who wish to screen embryos for chromosomal abnormalities.

7Preimplantation Genetic Testing for Monogenic disorders (PGT-M)
CategoryGenetic Testing Service
Description

A test that detects alteration or mutation of a particular gene that would cause a monogenic or Mendelian disorder, including autosomal recessive, autosomal dominant, and X-chromosome-linked diseases.

8Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)
CategoryGenetic Testing Service
Description

A test that detects rearrangements in the structure of an embryo's chromosomes, which can result in infertility, repetitive miscarriages, or genetic disorders.

9Non-Invasive Prenatal Test (NIPT)
CategoryGenetic Testing Service
Description

A non-invasive prenatal screening test that analyses the most common chromosomal abnormalities including Down Syndrome, Edwards Syndrome, Patau Syndrome, and sex chromosome abnormalities.

10Carrier Genetic Test (CGT)
CategoryGenetic Testing Service
Description

A test to identify mutations present in an individual, detecting recessive and X-linked mutations to determine compatibility between partners for having children.

11Sperm Aneuploidy Test (SAT)
CategoryGenetic Testing Service
Description

A diagnostic test that studies sperm chromosomes to detect cases in which there is an abnormal number of chromosomes.

12Products of Conception (POC) Testing
CategoryGenetic Testing Service
Description

A test that analyses the foetal tissue of a gestational loss to determine whether the miscarriage was the result of a chromosomal aneuploidy.

13Costco Membership Fertility Care Plan
CategorySubscription-based Fertility Care Product
Description

Subscription-based end-to-end fertility care, including virtual access to reproductive specialists and connections to in-person clinic services for advanced treatment, offered exclusively to Costco members in the United States.

14IVI RMA Global Education
CategoryEducation and Training Service
Description

Global education and training programs for reproductive medicine professionals, including postgraduate studies in collaboration with universities, online specialized courses, on-site clinic courses, and training and consulting services.

15IVI RMA Global Research Alliance
CategoryResearch Services
Description

The research division of IVI RMA Global with 7 research centers, 15 research areas, and over 150 researchers, dedicated to scientific research and technology development in reproductive medicine and ART.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-06-10
Description

IVI RMA Global is a campaign partner in the international 'Break the Taboo' campaign launching June 17, 2026, for World Infertility Awareness Month. The campaign builds on an inaugural campaign that engaged over 3 million people across six continents, with IVI RMA leveraging its international network of physicians, researchers, and clinics to amplify awareness of barriers to fertility care.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-07
Description

Costco partnered with Sesame and IVI RMA to offer affordable end-to-end fertility care through a monthly membership model starting at $119/month ($99 for Costco members). The partnership addresses a significant gap in employer fertility benefits, with IVF medications alone costing over $7,000 per cycle. Available exclusively to Costco members across the United States.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-07
Description

Healthcare self-pay marketplace partnered with Costco and IVI RMA to provide virtual access to reproductive specialists with connections to in-person clinic services for those needing specialized treatment. Addresses the high out-of-pocket costs associated with fertility treatments.

4RESOLVE: The National Infertility Association
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-04-17
Description

IVI RMA North America partnered with RESOLVE during National Infertility Awareness Week, with a portion of proceeds from the virtual pop-up shop donated to support infertility advocacy, education, and access to care.

businesswire.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

IVI RMA Global completed approximately $450 million acquisition of ART Fertility Clinics operations across UAE and Saudi Arabia. The deal strengthens IVI RMA's presence in the GCC region and supports expansion plans into Saudi Arabia, establishing Middle East as its fifth geographic market.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-22
Description

IVI RMA America acquired Eugin Group's North American operations for $535 million, strengthening IVI RMA's presence in the North American fertility market.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Inception Fertility
TypeDirect peer
Description

Inception operates a large US fertility clinic network (including Prelude Fertility and MyEggBank), positioned similarly to IVI RMA's US footprint with multi-brand strategy and physician network rollup approach.

TypeOthers
Description

Vitrolife is a leading supplier of ART media, consumables, and time-lapse incubator systems used by fertility clinics including IVI RMA; included as an adjacent ecosystem enabler in reproductive medicine.

TypeDirect peer
Description

TFP operates fertility clinics across the UK and parts of Europe, offering IVF, ICSI, and fertility preservation comparable to IVI RMA's UK (Create Fertility) and broader European footprint.

TypeDirect peer
Description

Canadian fertility clinic rollup backed by institutional capital pursuing the same multi-region consolidation strategy as IVI RMA Global, with acquired clinic brands retaining local identity.

TypeRegional player
Description

Australian-headquartered fertility clinic operator with proprietary embryo culture technology and global licensing, comparable to IVI RMA as a multi-clinic ART provider, though primarily serving the Asia-Pacific region.

TypeDirect peer
Description

Prelude operates a network of fertility clinics across the US focused on egg freezing and IVF, sitting under Inception Fertility but functioning as a comparable consumer-facing fertility brand like IVI RMA's RMA Network.

TypeDirect peer
Description

Shady Grove Fertility is one of the largest US fertility clinic operators, offering a comprehensive suite of IVF, IUI, donor egg, and genetic testing services with a shared-risk pricing program comparable to IVI RMA.

TypeDirect peer
Description

New Hope operates US fertility clinics emphasizing natural/minimal stimulation IVF protocols, overlapping with IVI RMA in core IVF services and competing for the same US patient population.

TypeDirect peer
Description

Boston IVF is now a wholly owned brand within IVI RMA but historically operated as an independent competitor; it remains a useful peer reference for US regional fertility clinic scale and brand strength.

TypeDirect peer
Description

CCRM operates a multi-region fertility clinic network with in-house IVF labs, PGT services, and reproductive endocrinology specialists, directly competing with IVI RMA in the US market with comparable clinical offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries21 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IVI RMA GLOBAL

Reproductive Medicine / Fertility Servicesivirma.com

What IVI RMA GLOBAL does

IVI RMA Global is a privately held reproductive medicine group operating the world's largest dedicated fertility treatment network. Formed in 2017 through the merger of Spain's IVI (founded 1990 by Profs. José Remohí and Antonio Pellicer) and the US-based RMA (founded 1999 by Drs. Paul Bergh, Richard Scott and Michael Drews), the company runs more than 200 clinical offices and 95+ laboratories across 15 countries in Europe, North America, Latin America, and (as of late 2025) the Middle East, performing 200,000+ assisted reproduction treatments annually and producing 100+ births per day.

The group's clinical platform spans core ART services (in vitro fertilization, intracytoplasmic sperm injection, artificial insemination, egg and sperm donation, fertility preservation including oocyte vitrification), advanced laboratory techniques (time-lapse embryo monitoring, MACS sperm selection, extended blastocyst culture), and a full genetic testing suite (PGT-A, PGT-SR, PGT-M, NIPT, carrier and sperm aneuploidy testing). It is supported by 7 research centers and 350+ researchers who have published 3,000+ scientific papers, alongside a global education division and the regional brands Boston IVF, Conceptions, Create Fertility, Genera, Demetra, Livio, Vitanova, Carl Von Linne, TRIO, Ferticare, Ginemed, Ginefiv, and Art Fertility.

IVI RMA generates revenue primarily from per-cycle clinical treatment fees across its global clinic network, supplemented by a recently launched US subscription membership product (with Costco and Sesame) priced at $99-$119 per month. The company is KKR-backed and has executed roughly $985M of M&A in 2025 alone, including the $535M Eugin North America acquisition and the ~$450M ART Fertility Clinics deal that established the Middle East as its fifth geographic region. Customers are overwhelmingly individual patients seeking fertility care, supplemented by enterprise partnerships with retailers, telehealth platforms, and advocacy organizations.

IVI RMA GLOBAL firmographics

Firmographics
Name
IVI RMA GLOBAL
Legal name
EQUIPO IVI, S. L.
Website
https://www.ivirma.com/
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
5,001–10,000 employees
Ownership category
akta.pro rank

IVI RMA GLOBAL industry classification

Industry
Product category
Reproductive Medicine / Fertility Services
NAICS
Family Planning Centers (621410), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)
SIC
Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro primary industry
Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)
akta.pro secondary industries
Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC), Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

Keywords

  • Assisted reproductive technology
  • In vitro fertilization
  • Fertility treatment services
  • Reproductive medicine clinics
  • Fertility preservation services

Where IVI RMA GLOBAL is headquartered

Location

Headquarters

HQ city
Valencia
HQ country
Spain
HQ region
Europe

Offices4 records

Markets served

IVI RMA GLOBAL business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Fertility Treatment Services: IVI RMA Global generates revenue through providing assisted reproductive services including IVF, artificial insemination, egg donation, fertility preservation, and related treatments. Services are offered through a network of 200+ clinical offices across 15 countries.
  2. Membership-based Fertility Care: Partnership with Costco and Sesame offers fertility care through a monthly membership model starting at $119 per month ($99 for Costco members), providing end-to-end fertility care including virtual access to reproductive specialists.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyCostco Membership Fertility Care Plan

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

IVI RMA GLOBAL product offering

Product offering

Core offering

IVI RMA Global operates a global network of fertility clinics providing assisted reproductive technology (ART) services including in vitro fertilization (IVF), artificial insemination, egg donation, fertility preservation, and preimplantation genetic testing. The group delivers these services through 200+ clinical offices and 95+ labs across 15 countries, supported by advanced laboratory techniques such as time-lapse embryo monitoring, ICSI, oocyte vitrification, MACS sperm selection, and extended embryo culture to blastocyst stage.

Product overview

IVI RMA Global is a comprehensive fertility care platform operating as the world's leading reproductive medicine group with a multi-brand, multi-region portfolio. The company offers a unified platform of assisted reproductive technology (ART) services comprising core clinical treatments (Artificial Insemination, In Vitro Fertilization, Egg Donation, Fertility Preservation), advanced laboratory techniques (Oocyte Vitrification, Time-Lapse Monitoring, ICSI, MACS, Extended Embryo Culture), and genetic testing services (PGT-A, PGT-SR, PGT-M, NIPT, Carrier Genetic Testing). The platform is organized across regional brands including IVI, RMA Network, Boston IVF, Conceptions, Ginemed, Ginefiv, Art Fertility, Create Fertility, Genera, Demetra, Livio, Vitanova, Carl Von Linne, TRIO Fertility, and Ferticare, spanning 15 countries with over 200 clinical offices and 95+ laboratories. The group also provides complementary services including global education programs (postgraduate studies, online courses, training & consulting) and research services through its Global Research Alliance (7 research centers, 15 research areas).

Differentiator

Problem solved

Functional benefit

Products and services

  • In Vitro Fertilization (IVF) A procedure uniting the ovum with the spermatozoon in the laboratory (in vitro) to obtain fertilized embryos for transfer to the mother's uterus, using either conventional IVF or ICSI. Offered to women and couples needing medical assistance to conceive.
  • Artificial Insemination A procedure in which a prepared semen sample is deposited inside the woman's uterus to increase the potential of the spermatozoa and improve the chance of fertilization. Offered to couples and individuals seeking less invasive fertility treatment.
  • Egg Donation
  • Fertility Preservation
  • Sperm Donation
  • Preimplantation Genetic Testing for Aneuploidies (PGT-A) A test that detects numerical alterations in an embryo's chromosomes, identifying whether there are more or fewer chromosomes than the normal 46. Offered to patients undergoing IVF who wish to screen embryos for chromosomal abnormalities.
  • Preimplantation Genetic Testing for Monogenic disorders (PGT-M) A test that detects alteration or mutation of a particular gene that would cause a monogenic or Mendelian disorder, including autosomal recessive, autosomal dominant, and X-chromosome-linked diseases.
  • Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR) A test that detects rearrangements in the structure of an embryo's chromosomes, which can result in infertility, repetitive miscarriages, or genetic disorders.
  • Non-Invasive Prenatal Test (NIPT) A non-invasive prenatal screening test that analyses the most common chromosomal abnormalities including Down Syndrome, Edwards Syndrome, Patau Syndrome, and sex chromosome abnormalities.
  • Carrier Genetic Test (CGT) A test to identify mutations present in an individual, detecting recessive and X-linked mutations to determine compatibility between partners for having children.
  • Sperm Aneuploidy Test (SAT) A diagnostic test that studies sperm chromosomes to detect cases in which there is an abnormal number of chromosomes.
  • Products of Conception (POC) Testing A test that analyses the foetal tissue of a gestational loss to determine whether the miscarriage was the result of a chromosomal aneuploidy.
  • Costco Membership Fertility Care Plan Subscription-based end-to-end fertility care, including virtual access to reproductive specialists and connections to in-person clinic services for advanced treatment, offered exclusively to Costco members in the United States.
  • IVI RMA Global Education Global education and training programs for reproductive medicine professionals, including postgraduate studies in collaboration with universities, online specialized courses, on-site clinic courses, and training and consulting services.
  • IVI RMA Global Research Alliance The research division of IVI RMA Global with 7 research centers, 15 research areas, and over 150 researchers, dedicated to scientific research and technology development in reproductive medicine and ART.

Quantifiable outcome

  • 100+ babies born daily thanks to IVI RMA Global
  • +2 more outcomes

Companies that use IVI RMA GLOBAL

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles3 records

IVI RMA GLOBAL technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

IVI RMA GLOBAL partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • World Fertility Project / pregnantishcoreGTM or Marketing Partner · 10 June 2026IVI RMA Global is a campaign partner in the international 'Break the Taboo' campaign launching June 17, 2026, for World Infertility Awareness Month. The campaign builds on an inaugural campaign that engaged over 3 million people across six continents, with IVI RMA leveraging its international network of physicians, researchers, and clinics to amplify awareness of barriers to fertility care.
  • CostcocoreGTM or Marketing Partner · 7 May 2026Costco partnered with Sesame and IVI RMA to offer affordable end-to-end fertility care through a monthly membership model starting at $119/month ($99 for Costco members). The partnership addresses a significant gap in employer fertility benefits, with IVF medications alone costing over $7,000 per cycle. Available exclusively to Costco members across the United States.
  • SesamecoreGTM or Marketing Partner · 7 May 2026Healthcare self-pay marketplace partnered with Costco and IVI RMA to provide virtual access to reproductive specialists with connections to in-person clinic services for those needing specialized treatment. Addresses the high out-of-pocket costs associated with fertility treatments.
  • RESOLVE: The National Infertility AssociationcoreGTM or Marketing Partner · 17 April 2026IVI RMA North America partnered with RESOLVE during National Infertility Awareness Week, with a portion of proceeds from the virtual pop-up shop donated to support infertility advocacy, education, and access to care.
  • ART Fertility ClinicsflagshipStrategic or Co-development Partner · 11 February 2026IVI RMA Global completed approximately $450 million acquisition of ART Fertility Clinics operations across UAE and Saudi Arabia. The deal strengthens IVI RMA's presence in the GCC region and supports expansion plans into Saudi Arabia, establishing Middle East as its fifth geographic market.
  • Eugin GroupflagshipStrategic or Co-development Partner · 22 January 2025IVI RMA America acquired Eugin Group's North American operations for $535 million, strengthening IVI RMA's presence in the North American fertility market.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

IVI RMA GLOBAL competitors and assessment

Company assessment

Direct peers

  • Inception Fertility: Inception operates a large US fertility clinic network (including Prelude Fertility and MyEggBank), positioned similarly to IVI RMA's US footprint with multi-brand strategy and physician network rollup approach.
  • TFP (The Fertility Partnership): TFP operates fertility clinics across the UK and parts of Europe, offering IVF, ICSI, and fertility preservation comparable to IVI RMA's UK (Create Fertility) and broader European footprint.
  • The Fertility Partners: Canadian fertility clinic rollup backed by institutional capital pursuing the same multi-region consolidation strategy as IVI RMA Global, with acquired clinic brands retaining local identity.
  • Prelude Fertility: Prelude operates a network of fertility clinics across the US focused on egg freezing and IVF, sitting under Inception Fertility but functioning as a comparable consumer-facing fertility brand like IVI RMA's RMA Network.
  • Shady Grove Fertility: Shady Grove Fertility is one of the largest US fertility clinic operators, offering a comprehensive suite of IVF, IUI, donor egg, and genetic testing services with a shared-risk pricing program comparable to IVI RMA.
  • New Hope Fertility Center: New Hope operates US fertility clinics emphasizing natural/minimal stimulation IVF protocols, overlapping with IVI RMA in core IVF services and competing for the same US patient population.
  • Boston IVF (pre-acquisition context): Boston IVF is now a wholly owned brand within IVI RMA but historically operated as an independent competitor; it remains a useful peer reference for US regional fertility clinic scale and brand strength.
  • CCRM Fertility: CCRM operates a multi-region fertility clinic network with in-house IVF labs, PGT services, and reproductive endocrinology specialists, directly competing with IVI RMA in the US market with comparable clinical offerings.

Others

  • Vitrolife: Vitrolife is a leading supplier of ART media, consumables, and time-lapse incubator systems used by fertility clinics including IVI RMA; included as an adjacent ecosystem enabler in reproductive medicine.

Regional players

  • Genea Group: Australian-headquartered fertility clinic operator with proprietary embryo culture technology and global licensing, comparable to IVI RMA as a multi-clinic ART provider, though primarily serving the Asia-Pacific region.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

IVI RMA GLOBAL financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IVI RMA GLOBAL leadership team

Management profile

Number of profiles

Profiles17 records

IVI RMA GLOBAL subsidiaries and ownership

Company hierarchy

Subsidiaries21 records

IVI RMA GLOBAL funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IVI RMA GLOBAL M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IVI RMA GLOBAL

What does IVI RMA GLOBAL do?

IVI RMA Global operates a global network of fertility clinics providing assisted reproductive technology (ART) services including in vitro fertilization (IVF), artificial insemination, egg donation, fertility preservation, and preimplantation genetic testing. The group delivers these services through 200+ clinical offices and 95+ labs across 15 countries, supported by advanced laboratory techniques such as time-lapse embryo monitoring, ICSI, oocyte vitrification, MACS sperm selection, and extended embryo culture to blastocyst stage.

Is IVI RMA GLOBAL a public or private company?

IVI RMA GLOBAL is a private company. It is classified as private equity controlled and is currently operating.

When was IVI RMA GLOBAL founded?

IVI RMA GLOBAL was founded in 1990. It employs 5,001 to 10,000 people.

Where is IVI RMA GLOBAL based?

IVI RMA GLOBAL is headquartered in Valencia, Spain, in the Europe region.

How does IVI RMA GLOBAL make money?

Two revenue lines are on record. Fertility Treatment Services are the primary driver. The others are membership-based Fertility Care.

Who are IVI RMA GLOBAL's main competitors?

Direct peers on record are Inception Fertility, TFP (The Fertility Partnership), The Fertility Partners, Prelude Fertility, Shady Grove Fertility, New Hope Fertility Center, Boston IVF (pre-acquisition context) and CCRM Fertility. Vitrolife is listed as an others. Genea Group is listed as a regional player.

Does IVI RMA GLOBAL have an API?

No public API is recorded for IVI RMA GLOBAL.

What industry is IVI RMA GLOBAL in?

IVI RMA GLOBAL's product category is Reproductive Medicine / Fertility Services. Its primary akta.pro industry code is HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers, with a secondary code of HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility). Its NAICS code is 621410 and its SIC code is 8093.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireIVI RMA North America Partners with Illume Fertility, Establishing New Presence in ConnecticutIVI RMA North America announced a partnership with Illume Fertility, a Connecticut-based fertility group with five locations. Illume's team includes nine board-certified specialists, and the partnership aims to expand IVI RMA's regional network. The collaboration is expected to improve access to fertility care across the Northeast.AInvestFertility Care Is Heating Up. There's No Public Stock to Own It.The fertility care market is expanding, but no public stock offers direct exposure. IVI RMA, the largest network, is private, and Hims & Hers, the closest public name, has not launched any fertility services. The company's stock has fallen 70% from its 52-week high, and it carries $3.3 billion in debt.NJBIZIVI RMA to debut automated IVF system AURA in US clinicIVI RMA Global and Conceivable Life Sciences have announced a partnership to introduce AURA, the first automation-assisted IVF laboratory system, at a U.S. clinic in 2027. As part of the agreement, IVI RMA made a strategic investment in Conceivable to support further development of the platform, which uses robotics and physical AI to standardize IVF laboratory processes. Pilot studies have treated more than 100 patients with over 1,000 eggs processed and have achieved live births, with plans to expand across IVI RMA's global network spanning 15 countries.Empresas de Capital Riesgo en EspaARCANO advised IVI RMA Global on its partnership with Conceivable Life SciencesARCANO advised IVI RMA Global on its partnership with Conceivable Life Sciences to deploy the first automated IVF laboratory in the US. The alliance will start at a US clinic in 2027, with expansion planned across Europe, Latin America, and the Middle East. The partnership aims to standardize laboratory processes and improve patient outcomes.Mirage NewsResearch: Uterine Ageing Impacts Over-49 PregnanciesResearchers from the IVIRMA Global Research Alliance at IVI Roma analyzed 2,760 donor-oocyte embryo transfers and found that women aged 49 and over had significantly lower live birth rates (31.7% vs 46.2%) and higher miscarriage rates (37.6% vs 24.2%) compared to women aged 35-40. The study identified age-related changes in the uterine endometrium, including a decline in the trilaminar endometrial pattern from 94.7% to 81.0%, suggesting that uterine ageing independently contributes to poorer reproductive outcomes even when egg quality is controlled. The findings, presented at ESHRE's 42nd Annual Meeting and to be published in Human Reproduction, indicate that donor eggs cannot completely eliminate the effects of reproductive ageing beyond age 49.HomepageIVI RMA Global Partners with Conceivable Life Sciences to Deploy First Automated IVF Lab in the U.S.IVI RMA Global and Conceivable Life Sciences announced a strategic partnership, including an investment by IVI RMA in Conceivable, to deploy AURA, a robotic IVF laboratory platform, at a U.S. clinic in 2027. AURA is designed to work alongside embryologists, performing hundreds of manual steps with machine precision to standardize embryo quality and reduce variability between labs and operators. The companies plan to expand the system across IVI RMA's network in Europe, Latin America, and the Middle East, building on pilot results including over 100 patients treated, more than 1,000 eggs processed, and live births achieved.AijournIVI RMA Global and Conceivable Life Sciences Announce Partnership to Deploy the First Automated IVF Lab in the USIVI RMA Global and Conceivable Life Sciences announced a strategic partnership to deploy Conceivable's AURA automated IVF laboratory system—the world's first automation-assisted robotic IVF platform—at a US clinic in 2027. As part of the agreement, IVI RMA has made a strategic investment in Conceivable to support further development of the technology. The collaboration aims to expand access to standardized, precision fertility care, with deployment planned to extend across IVI RMA's network in Europe, Latin America, and the Middle East following the initial US launch.PR NewswireIVI RMA Global and Conceivable Life Sciences Announce Partnership to Deploy the First Automated IVF Lab in the USIVI RMA Global and Conceivable Life Sciences announced a strategic partnership to deploy Conceivable's AURA automated IVF laboratory system at a US clinic in 2027, marking the first major fertility network to implement the automation-assisted robotic platform. IVI RMA has made a strategic investment in Conceivable to support additional development of the technology, which has already been validated in pilot studies with over 100 patients treated and live births achieved. The deployment will expand across IVI RMA's network in Europe, Latin America, and the Middle East following the initial US rollout.PR NewswireIVI RMA Global and Conceivable Life Sciences Announce Partnership to Deploy the First Automated IVF Lab in the USIVI RMA Global and Conceivable Life Sciences announced a partnership to deploy Conceivable's AURA automation-assisted IVF lab in a US clinic in 2027. The system, designed to work alongside embryologists, has been evaluated in pilot studies with over 100 patients and more than 1,000 eggs processed. Expansion is planned across IVI RMA's network in Europe, Latin America, and the Middle East.MorningstarIVI RMA Global and Conceivable Life Sciences Announce Partnership to Deploy the First Automated IVF Lab in the USIVI RMA Global and Conceivable Life Sciences announced a partnership to deploy the first automated IVF lab in the US, with AURA platform introduction in 2027. The system is designed to work alongside embryologists, and IVI RMA made a strategic investment in Conceivable. Expansion is planned across IVI RMA's network in Europe, Latin America, and the Middle East.